Anno I | Numero 5 | Settembre 2016
Comitato scientifico editoriale: Sergio Bracarda, Giacomo Cartenì, Giuseppe Procopio
Editore: Intermedia – Direttore Responsabile: Mauro Boldrini
Notizie dalla ricerca

Tumor mutational load and immune parameters across metastatic Renal Cell Carcinoma (mRCC) risk groups
Patients with metastatic renal cell carcinoma (mRCC) have better overall survival when treated with nivolumab, a cancer immunotherapy that targets the immune checkpoint inhibitor programmed cell death 1 (PD-1), rather than everolimus (a chemical inhibitor of mTOR and immunosuppressant). Poor-risk mRCC patients treated with nivolumab seemed to experience the greatest overall survival benefit, compared to patients with favorable or intermediate-risk, in an analysis of the CheckMate-025 …
Continua a leggere
Second-line treatment for metastatic clear cell renal cell cancer: experts' consensus algorithms
Second-line systemic treatment options for metastatic clear cell renal cell cancer (mccRCC) are diverse and treatment strategies are variable among experts. Our aim was to investigate the approach for the second-line treatment after first-line therapy with a tyrosine kinase inhibitor (TKI). Recently two phase III trials have demonstrated a potential role for nivolumab (NIV) and cabozantinib (CAB) in this setting. We aimed to estimate the impact of these trials on clinical decision making. Eleven international experts …
Continua a leggere
Checkpoint inhibitors and other novel immunotherapies for advanced renal cell carcinoma
The management of advanced renal cell carcinoma (RCC) has dramatically changed over the past decade. Therapies that target the vascular endothelial growth factor (VEGF) and mammalian target of rapamycin (mTOR) pathways have considerably expanded treatment options; however, most patients with advanced RCC still have limited overall survival. Increased understanding of the mechanisms of T cell-antigen recognition and function has led to the development of novel immunotherapies to …
Continua a leggere
Checkpoint Blockade – a New Treatment Paradigm in Renal Cell Carcinoma
Nivolumab is the first checkpoint inhibitor for the treatment of renal cell carcinoma (RCC), which is in line for approval in Europe. Despite its novelty in the treatment algorithm of RCC, it offers a whole new strategy of therapy management with safe applicability. The aim of this work was to review current data on checkpoint inhibitors in RCC and discuss future perspectives for this novel approach in RCC. A selective literature search was performed in the Pubmed database: Nivolumab is a first-in-class agent for …
Continua a leggere
Checkpoint inhibitors for renal cell carcinoma: current landscape and future directions
Immunotherapy with checkpoint inhibitors has arrived and begun to change the landscape of clinical oncology, including for patients with renal cell carcinoma. Specifically, drugs targeting the programmed death 1 and cytotoxic T-lymphocyte associated antigen pathways have demonstrated remarkable responses for patients in clinical trials. In this article, we review the most recent available data for immune checkpoint inhibitors for patients with renal cell carcinoma. We discuss potential strategies for …
Continua a leggere
Appuntamenti AIOM
XVIII Congresso Nazionale AIOM
Roma, 28 – 30 ottobre 2016
Link all'evento
Immunotherapy: Past, present and Future
Napoli, 26 settembre 2016
AIOM-AIRTUM: Presentazione Volume "I Numeri del Cancro in Italia 2016"
Roma, 27 settembre 2016
Immuno-Oncologia: Stato dell'arte e update
Bari, 29 settembre 2016
Evento riservato ai Soci della Puglia
Combinazioni e sequenze in terapia: Aspetti clinico-metodologici e farmacoeconomici
Roma, 29 – 30 settembre 2016
XII Congresso Regionale AIOM Sardegna
Oliena (NU), 30 settembre – 1 ottobre 2016
Micro-ambiente tumorale. Antiangiogenici e immunoterapia: miti e realtà
Milano, 11 ottobre 2016
Dialoghi sull'immunoterapia dei tumori dell'AIOM Campania
Benevento, 18 ottobre 2016
Dialoghi sull'immunoterapia dei tumori dell'AIOM Campania
Napoli, 20 ottobre 2016
Hot Topics in Oncologia 2016
Fiuggi (FR), 22 ottobre 2016
NeVento-01 – 1° Meeting Annuale sulle Neoplasie Vescicali Gruppo NeVe
Milano, 3 novembre 2016
4th International Conference 'Translational Research in Oncology'
Meldola (FC), 8 novembre 2016
Forlì, 9 – 11 novembre 2016
IV Meeting Uro-Oncologico: Update 2016 sui tumori urologici
Fano (PU), 11 – 12 novembre 2016
Nuove Frontiere Diagnostico-Terapeutiche nelle Neoplasie Polmonari, Renali e nel Melanoma
Varese, 12 novembre 2016
5th World Top Communications of the Year in Genito-Urinary Oncology
Arezzo, 17 – 18 novembre 2016
Questi e altri appuntamenti si possono consultare sul sito AIOM

Editore: Intermedia s.r.l. – Via Malta 12/b, 25124 Brescia – tel. 030 226105 fax 030 2420472 – Reg. Trib. di Brescia n. 35/2001 del 2/7/2001
Per contattare la redazione e commentare le notizie clicca qui: redazione
Per consultare i numeri arretrati della newsletter clicca qui: archivio
Per sospendere la ricezione di questa newsletter clicca qui: AIOM news RIMUOVI

Questo progetto è stato realizzato con il contributo di